VivoSim Labs VIVS
NASDAQ VIVS
$0.26 0.00 (-0.27%)
As of: Sep 17, 2026 · 3:59 PM EDT

VivoSim Labs (VIVS) Net Income towards Common Stockholders (2010 - 2026)

VivoSim Labs (VIVS) posted Net Income towards Common Stockholders of -$2.7 million for Q2 2026, up 13.22% on a QoQ basis from -$3.2 million in Q1 2026, and up 3.69% year-over-year from -$2.6 million in Q2 2025.

Analysis

VivoSim Labs (VIVS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

VivoSim Labs has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$2.7 million in Q2 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 3.69% year-over-year to -$2.7 million in Q2 2026; TTM through Jun 2026 was -$11.1 million, a 7.16% increase from a year earlier, with the FY2026 full-year figure at -$11.2 million, up 10.04% from the prior year.
  • Net Income towards Common Stockholders was -$2.7 million for Q2 2026 at VivoSim Labs, up from -$3.2 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$1.9 million in Q1 2022, with the low at -$7.6 million in Q1 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$3.4 million, with a median of -$3.2 million recorded in 2022.
  • The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders tumbled 297.8% in 2023, then soared 59.94% in 2024.
  • Over 5 years, Net Income towards Common Stockholders stood at -$3.2 million in 2022, then fell by 12.06% to -$3.6 million in 2023, then advanced by 4.36% to -$3.4 million in 2024, then rose by 21.93% to -$2.7 million in 2025, then decreased by 1.75% to -$2.7 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$2.7 million (Q2 2026), -$3.2 million (Q1 2026), and -$2.7 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn 241.00 Mn
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn 121.36 Mn
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn 198.40 Mn
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -760,000.00
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -13.20 Mn
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn -46.71 Mn
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn -426,000.00
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -4.28 Bn
10 VivoSim Labs 1.37 Mn 1.37 Mn - -2.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.74 Mn
Mar 31, 2026 -3.16 Mn
Dec 31, 2025 -2.69 Mn
Sep 30, 2025 -2.55 Mn
Jun 30, 2025 -2.84 Mn
Mar 31, 2025 -3.15 Mn
Dec 31, 2024 -3.45 Mn
Sep 30, 2024 -2.55 Mn
Jun 30, 2024 -3.34 Mn
Mar 31, 2024 -3.05 Mn
Dec 31, 2023 -3.60 Mn
Sep 30, 2023 -3.99 Mn
Jun 30, 2023 -4.04 Mn
Mar 31, 2023 -7.60 Mn
Dec 31, 2022 -3.22 Mn
Sep 30, 2022 -3.25 Mn
Jun 30, 2022 -3.21 Mn
Mar 31, 2022 -1.91 Mn
Dec 31, 2021 -3.50 Mn
Sep 30, 2021 -3.51 Mn